Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02113566 · ClinicalTrials.gov registry record · Phase 4

A Study Comparing the Efficacy and Safety of Orally Administered Ibuprofen and Placebo in Delayed Onset Muscle Soreness

A Phase 4 study of Delayed Onset Muscle Soreness, sponsored by Jean Brown Research.

Completed
Registry status
Phase 4
Development phase
60
Enrollment target
1
Study location

NCT02113566 is a Phase 4 study of Delayed Onset Muscle Soreness that has completed, run by Jean Brown Research. The registered enrollment target is 60 participants, above the 31-participant average among 3 other Delayed Onset Muscle Soreness trials with a reported enrollment target (94% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02113566, a Phase 4 study of Delayed Onset Muscle Soreness, has completed, sponsored by Jean Brown Research.

COMPLETED
Registry status
Phase 4
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The hypotheses to be tested are: Efficacy: Ibuprofen will be more effective than the Placebo in relieving muscle pain/soreness over 48 hour post-dosing with study medication. Safety: There will be no or minimal increased incidence of adverse events (AEs) with Ibuprofen versus and both will be well tolerated.

Interventions

  • DRUG Acetaminophen 1000mg

Study Locations (1)

Utah

  • Jean Brown Research - Salt Lake City

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2013-02
Est. Completion 2013-05
Phase Phase 4

Sponsor

Jean Brown Research

2 total trials

What the Registry Record Tells You About NCT02113566

The ClinicalTrials.gov registry entry for NCT02113566 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 31-participant average among 3 other Delayed Onset Muscle Soreness trials with a reported enrollment target (94% higher). The listed sponsor is Jean Brown Research, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Delayed Onset Muscle Soreness appearing as the primary indexed condition, and to 1 intervention - of which Acetaminophen 1000mg is the first listed.

NCT02113566 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT02113566 about?

NCT02113566 is a clinical study titled "A Study Comparing the Efficacy and Safety of Orally Administered Ibuprofen and Placebo in Delayed Onset Muscle Soreness". The hypotheses to be tested are: Efficacy: Ibuprofen will be more effective than the Placebo in relieving muscle pain/soreness over 48 hour post-dosing with study medication. Safety: There will be no or minimal increased incidence of adverse events (AEs) with Ibuprofen versus and both will be well t...

What is the current status of trial NCT02113566?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2013-02. Estimated completion is 2013-05.

What conditions does trial NCT02113566 study?

This clinical trial studies the following conditions: Delayed Onset Muscle Soreness.

What interventions are being tested in trial NCT02113566?

The interventions under investigation include: Acetaminophen 1000mg (DRUG).

Who is sponsoring clinical trial NCT02113566?

This trial is sponsored by Jean Brown Research, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02113566 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Delayed Onset Muscle Soreness

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.